Icovamenib (BMF-219) — oral menin inhibitor

Menin is a transcriptional regulator implicated in beta-cell biology that the company describes as a brake on cell proliferation and insulin production. Icovamenib (also called BMF-219) is a once-daily pill that binds menin covalently and takes that brake off for a while. The idea is the same one behind the rest of this category — get the body to rebuild its own insulin-producing capacity rather than importing cells from a donor or a stem-cell line — but it has Phase 2 human C-peptide data.

What the trial did

COVALENT-112 (NCT06152042) was an open-label Phase 2 study in adults aged 18–70 who had T1D and still had some measurable insulin production of their own: entry required a C-peptide of at least 0.2 nmol/L for people diagnosed within three years, or 0.08 nmol/L for those diagnosed three to fifteen years ago.³ Participants took icovamenib for just 12 weeks, then were followed drug-free for another 40 weeks.

What it found

In the group diagnosed within the previous three years and dosed at 200 mg, mean stimulated C-peptide AUC — the standard measure of how much insulin the pancreas can still produce on demand — was about 52% above baseline at Week 12.¹ Then the drug stopped. Forty weeks later, at Week 52, mean C-peptide AUC was still only about 7% below baseline, against the roughly 47% annual decline reported in historical placebo cohorts.² This is an uncontrolled observation; natural variation, disease duration and participant selection prevent a causal comparison with the historical decline.

At the American Diabetes Association's 86th Scientific Sessions (5–8 June 2026, per the company release), the company added translational data: cytokine profiling showed no evidence of systemic immune activation, with inflammatory markers stable or reduced through Week 52.² (A detailed HbA1c benefit was reported at those sessions for the separate type 2 diabetes study; the T1D HbA1c claim is only an undetailed summary bullet.)

Now the honest part

The 200 mg cohort was five people. The 100 mg cohort was six; the longer-diagnosed cohort was nine. The study was open-label. The randomized, placebo-controlled Part 2 was never completed, so roughly half the intended population was never studied.¹ The 47% comparator is a historical figure, not a control arm in this trial. Every number above comes from company press releases and a conference presentation — there is no peer-reviewed publication and no results posted on ClinicalTrials.gov.³ The 28 August 2026 registry update now lists the trial as completed, with actual enrollment of 37 and study completion on 18 July 2025.³ That administrative status does not supply a missing placebo comparison or demonstrate efficacy.

The liver-safety history

This is the part a person with T1D should read before anything else on this page. On 6 June 2024 the FDA placed the entire BMF-219 diabetes programme on a full clinical hold — COVALENT-111 in type 2 diabetes and COVALENT-112, the type 1 trial described above. The stated reason was possible drug-induced hepatotoxicity: liver injury signals seen in the completed dose-escalation phase of the type 2 study.⁴ Dosing and enrolment in the T1D trial stopped.¹⁴

The hold was lifted on 26 September 2024, roughly sixteen weeks later, and the diabetes trials resumed.⁵ We have no peer-reviewed account of what the liver findings actually were, how many people had them, or how severe they got — only the company's announcements of the hold and its lift. A resolved hold is not a disqualifying one, but "the FDA halted this drug over possible liver toxicity" is a permanent part of its record, and any future trial in T1D will have to clear that bar again. A drug whose whole mechanism is telling cells to divide is one to watch closely.

The unsolved problem is the same one

Even if icovamenib regrows beta cells, the immune system that destroyed the originals is still there. Biomea's own plan concedes the point: the announced next study includes an arm combining icovamenib with an immunosuppressive agent, alongside longer dosing (6–12 months at 200 mg) at the Barbara Davis Center, Joslin, UT Health San Antonio and the University of Miami.¹ That trial was targeted for the second half of 2026 and, as of 16 September 2026, is not registered on ClinicalTrials.gov — so we are not putting it on the calendar.

How we rank it

Icovamenib sits at the top of the regeneration category, but not by much and not for the reason a press release would suggest. Other entries here have human C-peptide data too. Icovamenib has a company-reported C-peptide signal in a very small uncontrolled cohort. Cross-trial differences do not establish superiority over other approaches, and C-peptide does not directly measure newly grown beta cells. Efficacy, durability and maturity scores therefore remain cautious. If the confirmatory Phase 2 opens, enrols properly, and includes a placebo arm, this record will change quickly — in one direction or the other.